WALTHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today announced that it will showcase its
latest product innovation, Quell® 2.0 Wearable Pain Relief Technology™, during a workshop at DTxDM East, and will
discuss using real world, patient generated data to improve outcomes for people living with chronic pain.
"We are excited to share how user feedback has helped shape innovation in our Quell technology, and how data collected from the
Quell Health Cloud is fueling scientific research into chronic pain," said Frank McGillin, Senior Vice President and CCO of
NeuroMetrix. "Quell 2.0 is smarter, more powerful and 50% smaller than its predecessor, and has a totally redesigned app to make it
even easier for people with chronic pain to experience drug-free relief."
About Quell
Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night
while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell has
been shown in multiple clinical studies to relieve chronic pain and, in a published study, 4 out of 5 users reported improvement in
chronic pain. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health
tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with
the Quell Health Cloud, which provides customized feedback and powers one of the world’s largest chronic pain databases. Quell is
available online and through select retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit NeuroMetrix.com.
Source: NeuroMetrix,
Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Neurometrix.ir@neurometrix.com
